BRNS

Barinthus Biotherapeutics plc. BRNS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 15 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-10.58M

Quarter to Jun 30

Free cash flow

$-8.09M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$7.84M total
M&G Plc
$5.20M0.0%
SC CHINA HOLDING Ltd
$937.5K0.0%
GLR Partners, LLC
$820.6K0.0%
DC Funds, LP
$423.9K0.0%
Rangeley Capital, LLC
$122.2K+16.1%
Johns Hopkins University
$80.7K0.0%
MORGAN STANLEY
$71.8K+4825.0%
Baird Financial Group, Inc.
$69.9K0.0%
CITADEL ADVISORS LLC
$50.7K-35.5%
HighTower Advisors, LLC
$24.7K0.0%
RENAISSANCE TECHNOLOGIES LLC
$16.5K-83.4%
XTX Topco Ltd
$9.8KNew
RHUMBLINE ADVISERS
$7.7K0.0%
TWO SIGMA SECURITIES, LLC
$7.3KNew
UBS Group AG
$665New
See all 15 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BRNS

Earnings Per Share

13fpro.ai/company/BRNS

Loading ratio trend…

BRNS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Barinthus Biotherapeutics plc.'s annual filings on SEC EDGAR.

Barinthus Biotherapeutics plc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$15.0M$-61.1M—
FY 2023$802.0K$-73.3M—
FY 2022$44.7M$5.3M-9.0%
FY 2021$268.0K$-50.9M—
FY 2020$4.8M$-17.7M—
Source: BRNS filings on SEC EDGAR →

BRNS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Barinthus Biotherapeutics plc. (BRNS): stock profile, AI score and financials

Barinthus Biotherapeutics plc. (BRNS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BRNS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 15 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), Barinthus Biotherapeutics plc. reports net income of $-10.6M, free cash flow of $-8.1M. Top institutional holders of BRNS by reported 13-F value include M&G Plc, SC CHINA HOLDING Ltd, GLR Partners, based on the most recent SEC filings. BRNS trades on the Nasdaq exchange and files with the SEC under CIK 1828185. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Barinthus Biotherapeutics plc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1828185 →